Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Receivables (2023 - 2025)

ARS Pharmaceuticals' Receivables history spans 3 years, with the latest figure at $25.3 million for Q4 2025.

  • For Q4 2025, Receivables rose 169.45% year-over-year to $25.3 million; the TTM value through Dec 2025 reached $25.3 million, up 169.45%, while the annual FY2025 figure was $25.3 million, 169.45% up from the prior year.
  • Receivables for Q4 2025 was $25.3 million at ARS Pharmaceuticals, down from $37.8 million in the prior quarter.
  • Across five years, Receivables topped out at $37.8 million in Q3 2025 and bottomed at $178000.0 in Q4 2023.
  • The 3-year median for Receivables is $10.0 million (2025), against an average of $15.7 million.
  • The largest annual shift saw Receivables skyrocketed 5184.83% in 2024 before it soared 169.45% in 2025.
  • A 3-year view of Receivables shows it stood at $178000.0 in 2023, then surged by 5184.83% to $9.4 million in 2024, then surged by 169.45% to $25.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Receivables are $25.3 million (Q4 2025), $37.8 million (Q3 2025), and $26.2 million (Q2 2025).